UCB stock after-hours at EUR 201.45: minus 1.73 percent versus the prior close
Published on 10/05/2026 at 22:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
UCB stock was at EUR 201.45 after-hours on October 5, 2026, at 10:03 p.m. CEST, down EUR 3.55, or 1.73 percent, versus the Lang & Schwarz prior close of EUR 205.00.
After-hours trading
The quoted price was recorded by Lang & Schwarz in Berlin time. The further course of after-hours trading at Lang & Schwarz until 11:00 p.m. CEST is shown by the continuously updated real-time quote of UCB stock.
Myasthenia gravis data
On September 29, UCB said it would present data from its myasthenia gravis portfolio at the AANEM Congress Annual Meeting and the Myasthenia Gravis Foundation of America Scientific Session, held from September 29 through October 2 in Orlando, Florida. The company said the presentations included analyses of minimal symptom expression for ZILBRYSQ and RYSTIGGO, patient-impact research on ocular myasthenia gravis, and interim Phase 1b data for investigational cizutamig. UCB identified itself in the release as listed on Euronext Brussels under the symbol UCB.
FDA designation for CIMZIA
In a September 9 release, UCB said the U.S. Food and Drug Administration had granted Breakthrough Therapy Designation to CIMZIA for preventing placenta-mediated adverse pregnancy outcomes in pregnant women with antiphospholipid syndrome who are positive for lupus anticoagulant. The designation was supported by preliminary evidence from the investigator-sponsored IMPACT study, and UCB noted that CIMZIA was not approved for this use. PR Newswire distributed the company announcement.
